Patents by Inventor Joseph Paul Bullock

Joseph Paul Bullock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
    Publication number: 20230139170
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: September 8, 2022
    Publication date: May 4, 2023
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kalliopi STASI
  • Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
    Patent number: 11478480
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: October 25, 2022
    Assignee: Novartis AG
    Inventors: Joseph Paul Bullock, Chinmay Maheshwari, Quintus Medley, Muneto Mogi, Michela Montecchi-Palmer, Kalliopi Stasi
  • CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF
    Publication number: 20220162170
    Abstract: The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: February 13, 2020
    Publication date: May 26, 2022
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Gregory MORANDI, Michael MUTZ, Kalliopi STASI, Christopher Stephen TOWLER
  • Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
    Publication number: 20200390767
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 17, 2020
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kali STASI
  • Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
    Publication number: 20200261457
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: February 13, 2020
    Publication date: August 20, 2020
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kali STASI
  • INTRAOCULAR IRRIGATING SOLUTIONS AND METHODS FOR TREATING CORNEAL EDEMA
    Publication number: 20090264375
    Abstract: One aspect of the present invention relates to methods of treating corneal edema comprising contacting a cornea with an ophthalmic irrigating composition comprising histidine. In certain embodiments, the ophthalmic irrigating compositions contact the corneal endothelium. Another aspect of the present invention relates to ophthalmic irrigating compositions for treating corneal edema comprising histidine and optionally, calcium glycerophosphate and/or glutathione disulfide.
    Type: Application
    Filed: December 19, 2008
    Publication date: October 22, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Mandar V. SHAH, Joseph Paul BULLOCK, Alan L. WEINER, Harli DOLLINGER
  • STABILIZED GLYCEROPHOSPHATE-CONTAINING SURGICAL IRRIGATING SOLUTION
    Publication number: 20090239957
    Abstract: One aspect of the present invention relates to stabilized irrigating compositions comprising sodium glycerophosphate and/or calcium glycerophosphate, and a bicarbonate salt. Another aspect of the present invention relates to methods of irrigating ocular tissues during a surgical procedure comprising bathing the intraocular tissues with an irrigating composition comprising sodium glycerophosphate and/or calcium glycerophosphate, and a bicarbonate salt.
    Type: Application
    Filed: December 19, 2008
    Publication date: September 24, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Mandar V. SHAH, Joseph Paul BULLOCK, Alan L. WEINER, Harli DOLLINGER, Simaben B. PATEL
  • Olopatadine formulations for topical administration
    Patent number: 7402609
    Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: July 22, 2008
    Assignee: Alcon, Inc.
    Inventors: Ernesto J. Castillo, Wesley Wehsin Han, Huixiang Zhang, Haresh G. Bhagat, Onkar N. Singh, Joseph Paul Bullock, Suresh C. Dixit
  • Olopatadine formulations for topical administration
    Patent number: 6995186
    Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: February 7, 2006
    Assignee: Alcon, Inc.
    Inventors: Ernesto J. Castillo, Wesley Wehsin Han, Huixiang Zhang, Haresh G. Bhagat, Onkar N. Singh, Joseph Paul Bullock, Suresh C. Dixit
  • Olopatadine formulations for topical administration
    Publication number: 20030055102
    Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Type: Application
    Filed: June 19, 2002
    Publication date: March 20, 2003
    Applicant: Alcon, Inc.
    Inventors: Ernesto J. Castillo, Wesley Wehsin Han, Huixiang Zhang, Haresh G. Bhagat, Onkar N. Singh, Joseph Paul Bullock, Suresh C. Dixit